BMY241122P60000
- 1.34
- 0.000.00%
Bristol-Myers Squibb Newsroom
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
Bristol-Myers Squibb Hits 14-month High
Merck Phase 3 Study of Winrevair in PAH Meets Primary Endpoint
S&P 500, Dow Hit Records Right After Open | Live Stock
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages
Bristol-Myers Squibb (NYSE:BMY) Increases 4.7% This Week, Taking One-year Gains to 24%
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Replimune Climbs After Updates on Lead Drug
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Optimism Over Global Healthcare Sector Rises: Jefferies
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock